OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
October 14, 2021
The collaboration between Intellia and SparingVision will work to develop genomic medicines for ocular diseases.
The Pharmaceutical Technology and BioPharm International editors host industry experts, highlighting trends and new technologies.
October 12, 2021
AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.
October 11, 2021
MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, signed an agreement with Cellecta to license its genome-editing tool.
October 08, 2021
Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.
October 06, 2021
New excipients for protein-based drug products reduce viscosity while maintaining protein stability.
The collaboration between Sunovion, Sumitomo Dainippon, and Otsuka will focus on four compounds designed to treat neuropsychiatric health conditions.
October 05, 2021
Merck and Ridgeback Biotherapeutics' oral antiviral medication reduced the risk of hospitalization or death from COVID-19 by 50% relative to placebo in a Phase III clinical study.
October 04, 2021
Takeda will use Selecta Bioscience’s ImmTOR platform to develop gene therapies for lysosomal storage disorders.
October 03, 2021
Reformulation strategies are useful tools for more than just stretching out the potential return on investment for a product.